ASP Isotopes (NASDAQ:ASPI) CFO Sells $126,719.52 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CFO Heather Kiessling sold 23,124 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $5.48, for a total value of $126,719.52. Following the transaction, the chief financial officer owned 709,376 shares of the company’s stock, valued at $3,887,380.48. This trade represents a 3.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

ASP Isotopes Stock Performance

Shares of ASP Isotopes stock opened at $5.37 on Monday. The business has a 50-day moving average of $5.06 and a 200 day moving average of $6.70. ASP Isotopes Inc. has a 12 month low of $3.92 and a 12 month high of $14.49. The stock has a market capitalization of $676.08 million, a price-to-earnings ratio of -2.51 and a beta of 3.59. The company has a debt-to-equity ratio of 0.77, a current ratio of 12.23 and a quick ratio of 12.20.

ASP Isotopes (NASDAQ:ASPI) last announced its earnings results on Friday, April 10th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.70). ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 161.55%. The firm had revenue of $33.32 million for the quarter, compared to analysts’ expectations of $2.03 million. As a group, sell-side analysts forecast that ASP Isotopes Inc. will post -0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Canaccord Genuity Group restated a “buy” rating and set a $11.00 target price on shares of ASP Isotopes in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $13.00.

Hedge Funds Weigh In On ASP Isotopes

Several hedge funds and other institutional investors have recently made changes to their positions in ASPI. Quantbot Technologies LP purchased a new position in shares of ASP Isotopes in the 3rd quarter valued at about $34,000. BNP Paribas Financial Markets boosted its stake in shares of ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares during the period. IFP Advisors Inc purchased a new position in shares of ASP Isotopes in the 4th quarter valued at about $48,000. Pictet Asset Management Holding SA purchased a new position in shares of ASP Isotopes in the 4th quarter valued at about $61,000. Finally, Close Asset Management Ltd purchased a new position in shares of ASP Isotopes in the 3rd quarter valued at about $72,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.